{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T05:04:50Z","timestamp":1698642290834},"reference-count":12,"publisher":"ALUNA","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Wiad Lek"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:p>The aim: The study aimed to conduct a retrospective analysis of unfavorable outcome rate and to search for clinical and anamnestic criteria for predicting glucocorticoid-resistant pulmonary sarcoidosis. \nMaterials and methods: There were examined 37 women and 31 men with stage II to III pulmonary sarcoidosis from 2018-2022. The mean patients\u2019 age was (35.7\u00b16.6) years. All patients underwent a chest computed tomography scan on the Toshiba Aquilion Prime CT scanner before the start of treatment and after the three-month glucocorticoid therapy. Anamnestic, age- and gender related factors of unfavorable treatment outcomes were studied. \nResults: Dyspnea (86%), coughing (67%), general weakness and fatigue (29%) on the background of maintaining the indicators of lung tissue density at the level of -893.5 Hounsfield units and above according to the chest computed tomography imaging represented the three-month treatment failure. Glucocorticoid-resistant sarcoidosis was most diagnosed in patients with stage III disease; the mean patients\u2019 age was (44.3\u00b13.2) years; B positive men prevailed; 85% of patients developed extrapulmonary manifestations; in 43% of cases, concomitant cardiovascular pathology was diagnosed. \nConclusions: Age, gender, comorbid conditions, extrapulmonary lesions, and blood type can be used as predictive criteria for GC-resistant sarcoidosis.<\/jats:p>","DOI":"10.36740\/wlek202309108","type":"journal-article","created":{"date-parts":[[2023,10,29]],"date-time":"2023-10-29T18:05:31Z","timestamp":1698602731000},"page":"1949-1954","source":"Crossref","is-referenced-by-count":0,"title":["RISK FACTORS FOR GC-RESISTANT PULMONARY SARCOIDOSIS"],"prefix":"10.36740","volume":"76","author":[{"given":"Mykola M.","family":"Ostrovskyy","sequence":"first","affiliation":[{"name":"IVANO-FRANKIVSK NATIONAL MEDICAL UNIVERSITY, IVANO-FRANKIVSK, UKRAINE"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kostiantin V.","family":"Shvets","sequence":"additional","affiliation":[{"name":"IVANO-FRANKIVSK NATIONAL MEDICAL UNIVERSITY, IVANO-FRANKIVSK, UKRAINE"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariana O.","family":"Kulynych-Miskiv","sequence":"additional","affiliation":[{"name":"IVANO-FRANKIVSK NATIONAL MEDICAL UNIVERSITY, IVANO-FRANKIVSK, UKRAINE"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iryna O.","family":"Savelikhina","sequence":"additional","affiliation":[{"name":"IVANO-FRANKIVSK NATIONAL MEDICAL UNIVERSITY, IVANO-FRANKIVSK, UKRAINE"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oleksandr I.","family":"Varunkiv","sequence":"additional","affiliation":[{"name":"IVANO-FRANKIVSK NATIONAL MEDICAL UNIVERSITY, IVANO-FRANKIVSK, UKRAINE"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Galyna Z.","family":"Korzh","sequence":"additional","affiliation":[{"name":"IVANO-FRANKIVSK NATIONAL MEDICAL UNIVERSITY, IVANO-FRANKIVSK, UKRAINE"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alla B.","family":"Zuban","sequence":"additional","affiliation":[{"name":"IVANO-FRANKIVSK NATIONAL MEDICAL UNIVERSITY, IVANO-FRANKIVSK, UKRAINE"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"22436","published-online":{"date-parts":[[2023]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"1. Gavrysyuk VK, Dziublyk AY, Merenkova EO et al. Prohresuyuchyy lehenevyy fibroz u svitli polozhen' klinichnoyi nastanovy ATS\/ERS\/JRS\/ ALAT 2022 ROKU [Progressive pulmonary fibrosis in 2022 ATS\/ERS\/JRS\/ALAT clinical guidelines]. Ukr. Pulmonol. J. 2022;30(4):51\u201357. doi: 10.31215\/2306-4927-2022-30-4-51-57 (in Ukrainian).","DOI":"10.31215\/2306-4927-2022-30-4-51-57"},{"key":"ref1","unstructured":"2. Gavrysyuk VK, Merenkova EO, Dziublyk AY et al. New approaches to the management of patients with pulmonary sarcoidosis. Ukr. Pulmonol. J. 2022;30(2-3):48\u201362."},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3. Drent M, Crouser ED, Grunewald J. Challenges of Sarcoidosis and Its Management. N. Engl. J. Med. 2021;385(11):1018-1032. doi: 10.1056\/ NEJMra2101555.","DOI":"10.1056\/nejmra2101555"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4. Gavrysyuk VK, Merenkova EO, Dziublyk AY et al. Refractory Pulmonary sarcoidosis: definition, diagnosis criteria, prevalence. Ukr. Pulmonol. J. 2022;2-3:23\u201330.","DOI":"10.1183\/13993003.congress-2023.pa1746"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"5. Tana C, Drent M, Nunes H. et al. Comorbidities of sarcoidosis. Ann Med. 2022;54(1):1014-1035. doi: 10.1080\/07853890.2022.2063375.","DOI":"10.1080\/07853890.2022.2063375"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"6. Zhou Y, Gerke AK, Lower EE et al. The impact of demographic disparities in the presentation of sarcoidosis: a multicenter prospective study. Respir Med. 2021;187:106564. doi: 10.1016\/j.rmed.2021.106564.","DOI":"10.1016\/j.rmed.2021.106564"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"7. Baughman RP, Valeyre D, Korsten P et al. ERS clinical practice guidelines on treatment of sarcoidosis. Eur Respir J. 2021;58(6):2004079. doi: 10.1183\/13993003.04079-2020.","DOI":"10.1183\/13993003.04079-2020"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8. Lee YC, Chang KY, Mirsaeidi M. State-level health disparity is associated with sarcoidosis mortality. J Clin Med. 2021;10:2366. doi: 10.3390\/ jcm10112366.","DOI":"10.3390\/jcm10112366"},{"key":"ref8","unstructured":"9. Harasimowicz M, GIlbert E, Yi S et al. Clinical Features of Patients with Sarcoidosis and Concomitant Connective Tissue Disease [abstract]. Arthritis Rheumatol. 2022; 74 (9)."},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"10. Patompong U, Jay RH, Eric M. Clinical Manifestations, Diagnosis, and Treatment of Sarcoidosis. Mayo Clin Proc Innov Qual Outcomes. 2019;3(3):358-375. doi: 10.1016\/j.mayocpiqo.2019.04.006.","DOI":"10.1016\/j.mayocpiqo.2019.04.006"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11. Carneiro Lopes M, Porto Amadeu T, Ribeiro-Alves M et al. Defining prognosis in sarcoidosis. Medicine (Baltimore). 2020;99(48):e23100. doi: 10.1097\/MD.0000000000023100.","DOI":"10.1097\/md.0000000000023100"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"12. Lundkvist A, Kullberg S, Arkema V. E. Differences in disease presentation between men and women with sarcoidosis: A cohort study. Respiratory Medicine. 2022;191:106688. doi:10.1016\/j.rmed.2021.106688.","DOI":"10.1016\/j.rmed.2021.106688"}],"container-title":["Wiadomo\u015bci Lekarskie"],"original-title":[],"language":"en","deposited":{"date-parts":[[2023,10,29]],"date-time":"2023-10-29T18:05:37Z","timestamp":1698602737000},"score":1,"resource":{"primary":{"URL":"https:\/\/wiadlek.pl\/wp-content\/uploads\/archive\/2023\/WiadLek2023i9.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":12,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023]]},"published-print":{"date-parts":[[2023,9]]}},"URL":"https:\/\/doi.org\/10.36740\/wlek202309108","archive":["Internet Archive"],"relation":{},"ISSN":["0043-5147"],"issn-type":[{"value":"0043-5147","type":"print"}],"subject":[],"published":{"date-parts":[[2023]]}}}